Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H E Wander

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Onkologie|August 1, 1986
Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancerH E Wander, D Meyer, P Schuff-Werner, et al.
Cancer|November 1, 1986
Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO)H E Wander, G A Nagel, H C Blossey, et al.
Klinische Wochenschrift|April 1, 1985
[Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies]H E Wander, H C Blossey, G A Nagel, et al.
Cancer|September 15, 1984
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetateH C Blossey, H E Wander, J Koebberling, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II study with etoposide in previously untreated advanced breast cancerH E Wander, W Rauschning, D Meyer, et al.
Cancer Treatment Reports|January 1, 1987
1,2,4-Triglycidylurazol in advanced breast cancer: a trial of the phase II study group of the Association of Medical Oncology, German Cancer SocietyH E Wander, W E Berdel, K Bremer, et al.
Onkologie|August 1, 1982
[Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer]H C Blossey, H E Wander, G A Nagel, et al.
Onkologie|August 1, 1982
[High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration]H C Blossey, H E Wander, G A Nagel, et al.
Onkologie|October 1, 1987
[Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study]H E Wander, U R Kleeberg, U Essers, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1984
Metastatic breast cancer with constantly low CEA blood levels. A subgroup with unfavorable prognosis?G Krieger, H E Wander, M Kneba, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Onkologie|August 1, 1986
Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancerH E Wander, D Meyer, P Schuff-Werner, et al.
Cancer|November 1, 1986
Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO)H E Wander, G A Nagel, H C Blossey, et al.
Klinische Wochenschrift|April 1, 1985
[Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies]H E Wander, H C Blossey, G A Nagel, et al.
Cancer|September 15, 1984
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetateH C Blossey, H E Wander, J Koebberling, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase II study with etoposide in previously untreated advanced breast cancerH E Wander, W Rauschning, D Meyer, et al.
Cancer Treatment Reports|January 1, 1987
1,2,4-Triglycidylurazol in advanced breast cancer: a trial of the phase II study group of the Association of Medical Oncology, German Cancer SocietyH E Wander, W E Berdel, K Bremer, et al.
Onkologie|August 1, 1982
[Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer]H C Blossey, H E Wander, G A Nagel, et al.
Onkologie|August 1, 1982
[High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration]H C Blossey, H E Wander, G A Nagel, et al.
Onkologie|October 1, 1987
[Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study]H E Wander, U R Kleeberg, U Essers, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1984
Metastatic breast cancer with constantly low CEA blood levels. A subgroup with unfavorable prognosis?G Krieger, H E Wander, M Kneba, et al.
Pageof 4